Skip to main content
EducationNews

What Is Ancillary Testing in Pathology?

By July 13, 2025November 17th, 2026No Comments

Last updated: November 2026

Ancillary testing in pathology means any test performed beyond the routine H&E-stained slide to help confirm a diagnosis, classify a disease or guide treatment. Common ancillary tests include special stains, immunohistochemistry (IHC), in situ hybridization (including FISH), flow cytometry, cytogenetics and molecular tests such as PCR and next-generation sequencing. The H&E slide is the starting point for nearly every diagnosis; ancillary tests answer the questions the H&E alone can’t.

In this article

Types of Ancillary Tests

Test What it does Example use
Special stains (histochemical stains) Highlight specific tissue components or organisms that are hard to see on H&E Identifying H. pylori in a gastric biopsy
Immunohistochemistry (IHC) Uses antibodies to detect specific proteins in tissue Identifying where a metastatic tumor started, or measuring estrogen and progesterone receptor status in breast cancer
In situ hybridization (ISH, FISH) Detects specific DNA or RNA sequences directly in the tissue Checking for HER2 gene amplification in breast cancer or ALK rearrangement in lung cancer
Flow cytometry Measures markers on individual cells in a liquid sample Classifying leukemias and lymphomas
Cytogenetics Examines chromosomes for structural changes Detecting chromosomal changes in blood cancers
Molecular testing (PCR, NGS) Analyzes DNA, RNA or gene activity in the tumor Identifying mutations, such as EGFR in lung cancer, that make a patient eligible for targeted therapy

Many of these tests, especially IHC and special stains, are run in the pathology lab itself. Molecular and genomic tests are often sent out to a specialized laboratory.

When Ancillary Tests Are Used

A pathologist reviews the H&E slide first. Ancillary testing comes in when a case needs more information to:

  • Confirm or refine a diagnosis, such as distinguishing between tumor types that look alike on H&E.
  • Classify a disease, such as subtyping a lymphoma.
  • Estimate prognosis, such as gene expression tests that predict how aggressive a cancer is likely to be.
  • Guide treatment, such as biomarker tests that determine whether a patient qualifies for a specific therapy.
  • Inform next steps after a negative result. For example, after a negative prostate biopsy in a man with ongoing risk factors, an epigenetic test such as MDxHealth’s Confirm mdx can help a urologist decide whether a repeat biopsy is needed.

Why Some Ancillary Tests Take Longer

In-house stains are usually quick. Send-out molecular tests take longer, and much of that delay happens outside the lab bench. Every extra day is a day a patient waits for answers. The most common causes:

  • Separate ordering systems. Send-outs often require a separate portal, a phone call or a fax, which adds steps and room for error.
  • Locating the tissue. The testing laboratory has to request the right block or slides from wherever the tissue is stored, which can add days.
  • Insufficient tissue. If the sample doesn’t have enough tumor or quality material, the test can come back as quantity not sufficient (QNS), which may mean a new biopsy and a delayed answer for the patient.
  • Tracking. When orders and results live in different systems, it’s harder to see where a test stands.

How Practices Get Results Faster

The fastest improvements usually come from fixing the logistics around the test, not the test itself:

  • Set standing orders. Practices that know which tests they want for certain diagnoses can define those criteria once, so the right tests aren’t forgotten or delayed.
  • Keep ordering in one connected workflow. When orders travel with the case history and patient identification, nothing needs to be re-entered or chased down.
  • Protect the tissue from the start. Better tissue handling at the biopsy means more usable material and fewer QNS results.
  • Track every order to the result. One place to see what was ordered, where the tissue is and when results are back.

That’s the approach behind Lumea’s molecular testing workflow for clinics, which connects send-out orders to the case and tracks them from request to result. For prostate biopsies, the Lumea BxBoard® protects tissue before it reaches the lab, so fewer send-outs come back incomplete. See the molecular and genomic testing partners available through Lumea in our Partner Marketplace.

Frequently Asked Questions

What does ancillary testing mean in pathology?

Ancillary testing means additional tests performed beyond the routine H&E slide, such as special stains, immunohistochemistry, FISH, flow cytometry and molecular testing, to help confirm a diagnosis, classify a disease or guide treatment.

What is the difference between ancillary and molecular testing?

Molecular testing is one type of ancillary testing. Ancillary testing is the broader category and also includes special stains, immunohistochemistry, flow cytometry and cytogenetics.

Is immunohistochemistry an ancillary test?

Yes. Immunohistochemistry is one of the most commonly used ancillary tests in surgical pathology.

How long do ancillary tests take?

It depends on the test. In-house stains are usually completed quickly, while send-out molecular and genomic tests can take days to weeks, depending on the test, the laboratory and how quickly the tissue reaches it.

Make Send-Outs Simpler

See how Lumea connects molecular orders, tissue and results in one workflow. Request information.

author avatar
Abigail Diepeveen Senior Director of Growth & Digital Strategy
Abigail Diepeveen is Senior Director of Growth & Digital Strategy at Lumea, where she has spent nearly a decade working at the intersection of digital pathology technology and the labs, pathologists, and clinicians who use it. She holds a Master of Science in Marketing with a Digital Marketing specialization from Western Governors University.

Leave a Reply

Stay current in digital pathology — subscribe to the Digital Diagnostic Digest Subscribe Free → ✕